Gene Therapies

After game-changing FDA news for its Huntington's therapy, uniQure's upsized $225M offering signals massive investor confidence and accelerates its mission.

Decades-old treatments for bladder cancer are failing. Now, a wave of gene and viral therapies is sparking a market revolution and offering new hope.

After a stunning FDA reversal for its Huntington's drug, uniQure seeks $150M. A look at the high-stakes financing behind a pipeline of hope and risk.

A projected 12.4% CAGR signals a boom in hematopoietic stem cell transplantation, but the real story lies in the science poised to overcome timeless hurdles.

uniQure's early trial data for AMT-260 shows promise in reducing severe seizures, but experts urge cautious optimism on the long road to a cure.

The biotech firm's revenue plummeted as losses soared. But behind the numbers is a calculated pivot to cancer therapy, fueled by a Nasdaq debut and new cash.

For decades, insomnia treatment meant risky sedatives. Now, a new class of drugs is revolutionizing sleep science, promising safer rest for millions.

BioCardia bets its future on Japan's fast-track approval for its heart therapy, a strategic pivot that could unlock global markets or break the bank.

A new drug from Cambrian Bio shows promise in activating a key metabolic switch. This could lead to treatments that burn fat while preserving muscle mass.

A 'dream team' of pharma veterans has raised $180M to advance a next-gen oral drug, promising to transform the multi-billion dollar IBD market.

With enhanced GMP cell banking suites, Minaris integrates manufacturing and testing in Philadelphia, aiming to accelerate development in the booming CGT market.

A Taipei delegation at BIO 2026 signals Taiwan's strategic pivot from manufacturing to R&D, seeking global partners for its late-stage drugs and platforms.

At BIO 2026, Transpire Bio isn't just presenting; it's pitching a new paradigm for medicine, using inhalation to tackle everything from diabetes to cancer.

German biotech Mallia Aesthetics reports impressive results for its hormone-free hair serum, but the real story lies in its resilient, science-first strategy.

With a new $400M debt facility, Dyne Therapeutics is accelerating two promising drugs for DMD and DM1, showcasing the power of strategic, non-dilutive financing.

Gene therapy firm uniQure plans a 2026 FDA submission for AMT-130, a potential first disease-modifying treatment for Huntington's, on an accelerated track.

Azitra is betting its future on a radical pivot, leveraging its science for cosmetics and biotech tools. Is this a savvy move for faster cash or a risky dilution of focus?

With 33% growth dwarfing industry norms, NNB Nutrition's integrated model and fermentation tech aren't just winning—they're rewriting the rules for wellness.

Opus Genetics unveils a multi-program gene therapy pipeline, backed by a robust financial runway, aiming to systematically dismantle inherited retinal diseases.